Monoclonal Antibody Shows Promise Against Multiple COVID-19 Variants
Monoclonal antibody SC27 effectively neutralizes various SARS-CoV-2 variants and related viruses.
Complete the form below to unlock access to ALL audio articles.
Summary
The monoclonal antibody SC27 effectively neutralizes numerous SARS-CoV-2 variants and related coronaviruses. Developed by researchers from Texas Biomed and collaborators, SC27 targets multiple sites on the spike protein, showing broad protection in lab tests and animal models. Human trials are needed to confirm its potential.
Key Takeaways
A monoclonal antibody appears effective at neutralizing the numerous variants of SARS-CoV-2, as well as related viruses in animals that could pose a threat if they were to begin spreading in people. The antibody, called SC27, was recently described in Cell Reports Medicine.
The finding opens the possibility of broader, more effective treatments to work against current and future COVID variants.
Monoclonal antibody SC27 was identified, developed and provisionally patented by a team of researchers led by Greg Ippolito, Ph.D., who recently joined Texas Biomedical Research Institute (Texas Biomed), from University of Texas at Austin. Other team leaders included Jason Lavinder, Ph.D., at UT and Ralph Baric, Ph.D., at University of North Carolina at Chapel Hill.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREE“Other COVID-19 antibodies have been rendered ineffective as SARS-CoV-2 has evolved over the past several years,” says Dr. Ippolito, an Associate Professor. “Our new study suggests the virus is less likely to escape this treatment because SC27 targets and attaches to multiple parts of the virus’s spike protein, including sections that are not mutating as frequently.”
SC27 appears to work in two ways: it blocks the ACE2 binding site, which the virus uses to bind to, enter and infect cells. It also binds to a hidden or “cryptic” site on the underside of the spike protein that is largely unchanged or “conserved” between variants, which means SC27 can broadly recognize variants and related viruses. This is critical because if an antibody’s shape does not match enough with a virus – like two puzzle pieces that don’t quite fit – the antibody can’t effectively neutralize the virus and the virus sneaks by the body’s immune defense system.
The researchers tested SC27 against 12 viruses, from the original SARS-CoV-2 to currently circulating variants, as well as related SARS-1 and several other coronaviruses found in bats and pangolins. The antibody was effective against all of them in a petri dish and protected mice against both variants tested.
“This makes it broader and more effective than any other monoclonal antibody reported in scientific literature to date and the former FDA-approved cocktails,” says Dr. Ippolito, adding the caveat that SC27 still needs to be tested in human clinical trials.
The team is looking to collaborate with industry to further develop the SC27 monoclonal antibody treatment, which could potentially benefit immunocompromised patients who are unable to get vaccines. It also could serve as an emergency treatment during future outbreaks of new variants or coronaviruses. Next steps would include preclinical studies in larger animal models, including nonhuman primates, which are the gold standard to evaluate how complete immune systems respond to a treatment before safely moving to human clinical trials.
Notably, SC27 was found in individuals following vaccination with mRNA COVID-19 vaccines. Previously, this type of “class 1/4” antibody – which attaches to two distinct areas or “epitopes” of the spike protein – was only detected following natural infection from SARS-1.
“This is fantastic news that vaccines can prompt the generation of these more robust and effective antibodies,” explains Dr. Ippolito. “It means that future vaccine development can be tailored to generate these antibodies and have a clear metric for measuring which vaccines will be most effective.”
Reference: Voss WN, Mallory ML, Byrne PO, et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell Rep Med. 2024;5(8):101668. doi: 10.1016/j.xcrm.2024.101668
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.
This content includes text that has been generated with the assistance of AI. Technology Networks' AI policy can be found here.